Ankita Patro

Ankita Patro

Auto-generated profile, based on publicly available information

Ankita Patro

Department of Otolaryngology–Head and Neck Surgery, Vanderbilt University Medical Center

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2022 in The Laryngoscope
Verified
Journal Article
Closed access
NLNathan R. Lindquist
Nathan R. Lindquist
JHJourdan T. Holder
Jourdan T. Holder
APAnkita Patro
Ankita Patro
NCNathan D. Cass
Nathan D. Cass
KTKareem O. Tawfik
Kareem O. Tawfik
EPElizabeth L. Perkins
Elizabeth L. Perkins

12 June 2021 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MHMatthew R. Hoffman
Matthew R. Hoffman
APAnkita Patro
Ankita Patro
LHLi‐Ching Huang
Li‐Ching Huang
SCSheau‐Chiann Chen
Sheau‐Chiann Chen
LBLynn D. Berry
Lynn D. Berry
NCNorth American Airway Collaborative
North American Airway Collaborative

1 April 2017 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
LLLuis E. De León
Luis E. De León
CMCarlos M. Mery
Carlos M. Mery
RVRaymond A. Verm
Raymond A. Verm
DTDaniel Trujillo-Díaz
Daniel Trujillo-Díaz
APAnkita Patro
Ankita Patro
CFCharles D. Fraser
Charles D. Fraser
Optimal management of patients with congenitally corrected transposition of the great arteries (ccTGA) is unclear. The goal of this study was to compare the outcomes in patients with ccTGA undergoing different management strategies. Patients with ccTGA believed suitable for biventricular circulation, treated between 1995 and 2016, were included. The cohort was divided into 4 groups: systemic right ventricle (RV) (patients without surgical intervention or with a classic repair), anatomic repair, Fontan palliation, and patients receiving only a pulmonary artery band (PAB) or a shunt. Transplant-free survival from presentation was calculated for each group. The cohort included 97 patients: 45 (46%) systemic RV, 26 (27%) anatomic repair, 9 (9%) Fontan, and 17 (18%) PAB/shunt. Median age at presentation was 2 months (range 0 days to 69 years) and median follow-up was 10 years (1 month to 28 years). At initial presentation, 10 (11%) patients had any RV dysfunction (8 mild, 2 severe), and 16 (18%) patients had moderate or severe tricuspid regurgitation (TR). During the study, 10 (10%) patients died, and 3 (3%) patients underwent transplantation. At last follow-up, 11 (11%) patients were in New York Heart Association class III/IV, 5 (5%) had moderate or severe systemic ventricle dysfunction, and 16 (16%) had moderate or severe systemic atrioventricular valve regurgitation. Transplant-free survivals at 10 years were 93%, 86%, 100%, and 79% for systemic RV, anatomic repair, Fontan palliation, and PAB/shunt, respectively (p = 0.33). On multivariate analysis, only systemic RV dysfunction was associated with a higher risk for death or transplant (p = 0.001). Transplant-free survival in ccTGA appears to be similar between patients with a systemic RV, anatomic repair, and Fontan procedure. Systemic RV dysfunction is a risk factor for death and transplant.

26 October 2022 in The Laryngoscope
Verified
Journal Article
Open access
MHMatthew R. Hoffman
Matthew R. Hoffman
APAnkita Patro
Ankita Patro
LHLi‐Ching Huang
Li‐Ching Huang
SCSheau‐Chiann Chen
Sheau‐Chiann Chen
LBLynn D. Berry
Lynn D. Berry
NCNorth American Airway Collaborative
North American Airway Collaborative
Objectives: Serial intralesional steroid injection (SILSI) has been increasingly used to treat idiopathic subglottic stenosis (iSGS). Prior studies have shown effectiveness, but not in all patients. This multi‐institutional study evaluates the effect of SILSI on time to recurrent operation, peak expiratory flow (PEF), and dyspnea.Methods: Post‐hoc secondary analysis of the North American Airway Collaborative data were performed to evaluate the outcomes of iSGS patients undergoing and not undergoing SILSI. The primary outcome was time to recurrent operation, evaluated using Kaplan–Meier curves and Cox regression analysis. Secondary outcomes were change in PEF and clinical chronic obstructive pulmonary disease questionnaire (CCQ) score. Within patients undergoing SILSI, demographics, time from last procedure, and PEF at initiation of SILSI were evaluated to determine the effect on recurrence.Results: Two hundred and ninety patients were included, 238 undergoing endoscopic dilation alone and 52 undergoing dilation and SILSI. No differences in baseline characteristics were observed. There was no difference in time to recurrence (hazard ratio: 0.64; p = 0.183). There were no differences in PEF or CCQ across the 2.5‐year study period. Among 52 patients undergoing SILSI, PEF at the time of starting SILSI did not affect recurrence (χ2 = 0.09, p = 0.77).Conclusion: Patients undergoing and not undergoing SILSI had similar times to recurrence, PEF, and CCQ. Factors predicting recurrence among patients undergoing SILSI were not identified. These results support a randomized controlled trial with a uniform SILSI protocol to quantify the effects of SILSI on objective and subjective outcomes and help determine which iSGS patients benefit most.Level of Evidence: 3 Laryngoscope, 133:2255–2263, 2023

17 May 2021 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
APAnkita Patro
Ankita Patro
SCShane Carr
Shane Carr
MSMadelyn Stevens
Madelyn Stevens
KLKelly C. Landeen
Kelly C. Landeen
NCNathan D. Cass
Nathan D. Cass
DHDavid S. Haynes
David S. Haynes

1 September 2022 in Otology & Neurotology
Verified
Journal Article
Closed access
APAnkita Patro
Ankita Patro
NLNathan R. Lindquist
Nathan R. Lindquist
KTKareem O. Tawfik
Kareem O. Tawfik
MOMatthew R. O’mAlley
Matthew R. O’mAlley
MBMarc L. Bennett
Marc L. Bennett
EPElizabeth L. Perkins
Elizabeth L. Perkins
Objective: To characterize the influence of expanding indications on the profile of adults undergoing cochlear implantation (CI) at a high-volume CI center. Study Design: Retrospective review. Setting: Tertiary referral center. Patients: 774 adults undergoing CI evaluation from August 2015 to August 2020. Main Outcome Measures: Demographics; audiometry; speech recognition; speech, spatial, and qualities of hearing scale (SSQ-12). Results: Of 745 (96.3%) patients qualifying for implantation, 642 (86.6%) pursued surgery. Median age at evaluation was 69 years; 56.3% were men; 88.2% were Caucasian. Median distance to our center was 95 miles. The majority (51.8%) had public insurance (Medicare, Medicaid), followed by private (47.8%) and military (0.4%). Mean PTA, CNC, and AzBio in quiet and noise for the ear to be implanted were 85.2 dB HL, 15.0%, and 19.2% and 3.5%, respectively. Hybrid/EAS criteria were met by 138 (18.5%) CI candidates, and 436 (77.0%) unilateral CI recipients had aidable contralateral hearing for bimodal hearing configurations. Younger age (odds ratio [OR], 0.96; 95% confidence interval, 0.93–0.99) and non-Caucasian race (OR, 6.95; 95% confidence interval, 3.22–14.98) predicted candidacy. Likelihood of surgery increased for Caucasian (OR, 8.08; 95% confidence interval, 4.85–13.47) and married (OR, 2.28; 95% confidence interval, 1.50–3.47) patients and decreased for those with public insurance (OR, 0.45; 95% confidence interval, 0.29–0.69). A lower SSQ-12 score predicted both candidacy and surgery. Conclusion: Despite expansions in criteria, speech understanding remained extremely low at CI evaluation. Younger age and non-Caucasian race predicted candidacy, and Caucasian, married patients with private insurance and lower SSQ scores were more likely to pursue surgery.